PATOS Research Center
Pathophysiology and Treatment of Stroke
Project – Dr. Van der Schyf
Dr. Van der Schyf has developed a novel compound (NGP1-01) with a unique multiple mechanism of action and significant promise for the treatment of stroke. NGP1-01 modulates Ca 2+ influx into neurons – a major death trigger in cerebral ischemia – through multiple ion channels simultaneously . The L-type Ca 2+ channel, NMDA channel, sodium channel, and the slow outward potassium channel, are all drug targets in ischemia. Current drugs target these channels separately while NGP1-01 targets them simultaneously . Very early evidence also suggests that NGP1-01 binds at a novel site within the NMDA channel pore. The PATOS team has initiated a series of in vivo experiments in the MCAO mouse stroke model (below). The results are very promising and point to NGP1-01 as a potential neuroprotective drug in acute cerebral ischemic events such as brain stroke.
1) Establish novel experimental methods to further boost competitiveness. These include synthesis of drug derivatives, perfection of existing stroke models (e.g. by microdialysis), and the addition of an ischemia/reperfusion model and a model for traumatic brain injury.
2) The Center members will enhance visibility and recognition by presenting their work in publications and presentations on scientific congresses. We expect that the Center will give rise to a minimum of three publications by its members each year. At least one of these publications will come from collaborative projects and will be co-authored by at least two members of the Center.
3) P.I.s will strive to obtain extramural funding for individual projects within three years of membership in the Center. After successful funding of several Center members is obtained, an application for a NIH Program Project will be pursued.